Clinical Trials at Abramson Cancer Center of the University of Pennsylvania
As of September 2026, 23 paid clinical trials are recruiting at Abramson Cancer Center of the University of Pennsylvania, located at 51 N 39TH ST, PHILADELPHIA, PA 19104-2640, phone (215) 796-4640 in Philadelphia, Pennsylvania. Active studies at this site cover conditions such as Breast Cancer, Ovarian Cancer and Heart Failure. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Philadelphia
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
24 clinical trials at Abramson Cancer Center of the University of Pennsylvania
·Clear filters·A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
SynKIR-310 for Relapsed/Refractory B-NHL
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer
Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer
Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma
SBRT With Atezo/Bev for HCC
Healthy Volunteers Study
Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk
CTNNA1 Familial Expansion Study
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
Ovarian Tissue Transplantation
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
The CArdiovascular Risk Evaluation in Men With Prostate Cancer Study (CARE-PC) Pilot Feasibility Study
Common conditions studied in Philadelphia
- Breast Cancer (37 active studies)
- Cancer (23 active studies)
- Ovarian Cancer (23 active studies)
- Heart Failure (22 active studies)
- Prostate Cancer (21 active studies)
- Advanced Solid Tumor (19 active studies)
Leading research sponsors in Philadelphia
- University of Pennsylvania
- Abramson Cancer Center at Penn Medicine
- Children's Hospital of Philadelphia
- Thomas Jefferson University
- National Cancer Institute (NCI)
Frequently asked questions
How many paid clinical trials are currently recruiting in Philadelphia?
There are approximately 1,988 recruiting clinical trials in Philadelphia, Pennsylvania listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Philadelphia pay participants?
Most recruiting trials in Philadelphia compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Philadelphia?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Philadelphia?
The most common conditions under active study in Philadelphia include Breast Cancer (37), Cancer (23), Ovarian Cancer (23), Heart Failure (22), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Philadelphia?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Philadelphia on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Philadelphia?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Philadelphia?
Recruiting research sites in Philadelphia include University of Pennsylvania, Children's Hospital of Philadelphia, Thomas Jefferson University Hospital, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Philadelphia right now?
The largest active categories in Philadelphia are Cancer & tumors (555), Cardiovascular (113), Neurology & pain (106). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Abramson Cancer Center of the University of Pennsylvania?
Abramson Cancer Center of the University of Pennsylvania is located at 51 N 39TH ST, PHILADELPHIA, PA 19104-2640. Use the Google Maps link in the intro above to get directions.
How do I contact Abramson Cancer Center of the University of Pennsylvania?
You can reach Abramson Cancer Center of the University of Pennsylvania by phone at (215) 796-4640. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.